Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: Relmada is a clinical-stage biotechnology company focused on developing esmethadone (REL-1017), an NMDA receptor antagonist for depression, and a modified-release psilocybin formulation (REL-P11) for metabolic indications. The company has no commercial products and has not generated revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(39,596,248) | $(51,624,530) |
| Loss Per Share (Basic & Diluted) | $(1.31) | $(1.72) |
| Total Operating Expenses | $41,806,644 | $54,180,335 |
| Research & Development (R&D) | $24,026,395 | $29,601,215 |
| General & Administrative (G&A) | $17,780,249 | $24,579,120 |
| Cash Used in Operating Activities | $(26,299,773) | $(29,778,363) |
| Cash and Cash Equivalents (End of Period) | $2,086,260 | $14,469,354 |
| Short-Term Investments | $68,351,069 | $92,232,292 |
| Total Liquidity (Cash + Investments) | $70,437,329 | $106,701,646 |
| Accumulated Deficit | $(600,498,929) | $(513,735,465) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $12.4 million (23%) compared to the prior year period. This was driven by a $5.6 million decrease in R&D and a $6.8 million decrease in G&A.
- R&D Drivers: The reduction in R&D expenses is primarily due to the completion of the long-term open-label Study 310 and the RELIANCE I and III trials in late 2022/2023. This was partially offset by a $1.7 million increase in other research expenses associated with the ramp-up of new studies (302 and 304).
- G&A Drivers: The decrease in G&A was largely attributed to a $6.6 million reduction in stock-based compensation expense.
- Investment Activity: The company sold $32.4 million of short-term investments and purchased $8.3 million, resulting in a net cash inflow from investing activities of $24.1 million.
- Stock-Based Compensation: Total stock-based compensation for the six months was $15.5 million, down from $22.5 million in the prior year.
Outlook, Risks, and Management Commentary
- Liquidity Position: Management believes existing cash and short-term investments ($70.4 million) are sufficient to fund operations for at least 12 months from the filing date. No additional financing is currently required, though future funding may be needed for subsequent clinical trials.
- Clinical Pipeline:
- Esmethadone (REL-1017): The company is conducting two ongoing Phase 3 adjunctive trials (RELIANCE II and RELIGHT). An interim analysis of RELIANCE II is expected by year-end 2024. Previous Phase 3 trials (RELIANCE I and III) did not meet primary endpoints.
- Psilocybin (REL-P11): The company plans to initiate a Phase 1 trial in obese subjects in 2024 to evaluate a modified-release formulation for metabolic indications.
- Risks: The company faces standard biotechnology risks, including the uncertainty of clinical trial outcomes, regulatory approval, and the need for future capital raises. There is no assurance that products will be approved or commercially viable.
- Commitments: The company has license agreements requiring potential milestone payments (up to $160 million for the psilocybin program) and royalties. It also has ongoing lease obligations and quarterly payments to licensors.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity projection against current burn rates and potential delays in clinical trials.
- Clinical Milestones: Monitor the upcoming interim analysis of the RELIANCE II trial and the initiation of the REL-P11 Phase 1 trial.
- Capital Needs: Assess the likelihood of future equity dilution or debt financing required to complete the Phase 3 program and advance the psilocybin pipeline.
- Stock-Based Compensation: Review the $39.2 million of unrecognized stock-based compensation expense related to unvested options, which will impact future earnings.
- License Obligations: Confirm the status of milestone triggers and royalty obligations under the Arbormentis and Inturrisi/Manfredi agreements.